A 69-year-old woman was diagnosed with sarcoidosis, which was not treated with corticosteroid therapy. Her levels of angiotensin converting enzyme decreased significantly over 4 years and a mass lesion was detected near the lower part of her left main bronchus, and diagnosed as small cell lung cancer (SCLC). Treatment of the SCLC with a series of chemotherapeutic agents produced excellent results. The pulmonary sarcoidosis did not show any deterioration despite the frequent use of amrubicin, which is known to be a cause of interstitial pneumonia. This is a case report of SCLC complicated with sarcoidosis in a stage of spontaneous remission, possibly suggesting an association between sarcoidosis and tumor immunity, since recent reports have suggested that immune checkpoint inhibitors might be involved in the development of sarcoidosis. (J Nippon Med Sch 2018; 85: 291 296) 
Introduction
Sarcoidosis is a disease of unknown cause characterized by the formation of non-caseating epithelioid cell granulomas in all organs of the body. The relationship between sarcoidosis and the development of cancer has been discussed for many years, but remains unclear. Steinfort et al. reported that the presence of sarcoid reactions in the regional lymph nodes in lung cancer resulted in a better prognosis 1 . In recent years, numerous cases have been reported in which patients with cancer treated with immune checkpoint inhibitors developed sarcoidosis, suggesting that sarcoidosis might be linked to tumor immunity 2 9 . Herein, we report a case of small cell lung cancer (SCLC) complicated with sarcoidosis during a stage of spontaneous remission that demonstrated a remarkable positive response to chemotherapy.
Case Report
In 2012, a 69-year-old woman was referred to our hospital due to bilateral hilar lymphadenopathy (BHL) with widespread reticular shadows in both lung fields, as observed on an annual chest X-ray examination (Fig. 1a) per lobe (B3) revealed non-caseating epithelioid cell granulomas containing giant cells (Fig. 1b) ; thus, she was diagnosed with sarcoidosis. The patient was followed-up for 4 years without oral corticosteroid therapy for pulmonary sarcoidosis but with local treatment for eye and skin lesions due to sarcoidosis. The serum ACE levels gradually decreased from 54.6 to 25.6 IU/L (Fig. 1c) , even though she did not take any ACE inhibitors. (Fig. 2a) , in the lymph node just above the cardia, and on the right side of the upper abdominal aorta. The patient's serum neuron-specific enolase (NSE) and pro-gastrin releasing peptide (pro-GRP) levels were elevated to 19.1 ng/mL (normal range: 0 12 ng/mL) and 6,220 pg/mL (normal range: 0 80 pg/mL), respectively.
Histological examination of the bronchoscopic biopsy specimen obtained from the left main bronchus showed proliferation of small cells with a high nucleus-cytoplasm ratio that were positive for CD56 and synaptophysin (Fig. 2b) . On the basis of these findings, the patient was diagnosed with extensive-stage SCLC with abdominal lymph node metastasis (T2bN3M1c) in a stage of spontaneous remission from sarcoidosis (Fig. 1c) . The mass around the bronchus of the left lower lobe and the lymph node metastases were dramatically reduced after four courses of chemotherapy consisting of intravenous administration of cisplatin and etoposide, and showed almost complete response. The NSE and pro-GRP levels were also normalized. Thereafter, the patient was given amrubicin monthly due to refractory relapse of SCLC and was maintained under complete response for more than 1 year (Fig. 3a and b) . The pulmonary sarcoidosis was found to be similar before and after the chemotherapeutic treatment. It should be noted that amrubicin had no effect on either pulmonary sarcoidosis or fibrotic markers during the chemotherapy (Fig. 4a and b) .
Discussion
The association of sarcoidosis with malignant tumors has been debated for many years. Recently, a meta-analysis found that the relative risk of lung cancer increases within 4 years after the diagnosis of sarcoidosis 10 , which is similar to that observed in our case. Seven cases of concomitant occurrence of sarcoidosis and SCLC have been reported (Table 1) 11 17 . The onset of SCLC occurred within 2 to 12 years after the diagnosis of sarcoidosis. It is also important to note that although amrubicin is not generally recommended for treatment of lung cancer with interstitial pneumonia, as it may exacerbate the pneumonia 24 , its safety in cases of pulmonary sarcoidosis has not been evaluated yet. In our case, monthly amrubicin therapy lasting for more than 1 year did not affect serum fibrotic markers and pulmonary sarcoidosis, suggesting that amrubicin might be tolerable for fibrotic inflammation caused by sarcoidosis. It is interesting that both first-line and second-line chemotherapy showed remarkable effects against SCLC during the natural remission stage of sarcoidosis for over 18 months.
In conclusion, we described a case of SCLC complicated with sarcoidosis in a stage of spontaneous remission. It may be necessary to follow up patients with sar- Fig. 4 Effect of chemotherapy on pulmonary sarcoidosis (a) and fibrotic markers (b). a. Computed tomography (CT) scans at the initial visit, before and after chemotherapy. A chest CT showing bilateral hilar lymphadenopathy with widespread reticular shadows in both lung fields on initial admission to our hospital (left), which had been in remission before chemotherapy (middle), and did not deteriorate during chemotherapy (right). b. No changes was noted in the levels of fibrotic markers, Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D), during the chemotherapy. coidosis over the course of spontaneous remission for the possibility of carcinogenesis, especially those with a history of smoking.
